Cornerstone Therapeutics has signed an agreement to acquire exclusive US marketing rights to Pertzye (pancrelipase) from Digestive Care (DCI). Pertzye, the pancreatic enzyme product, is indicated for the treatment of exocrine pancreatic ...
Tags: Cornerstone, Digestive Care
Sanofi Pasteur and KaloBios Pharmaceuticals have announced the issuance of FDA fast track designation for novel biologic candidate KB001A targetting Pseudomonas Aeruginosa (Pa). An antibody fragment KB001A is developed against Pa that ...
Tags: Sanofi Pasteur, KB001A
N30 Pharmaceuticals has selected Greenphire's global payment technology platforms, eClinicalGPS and ClinCard, to streamline payments to investigators and subjects throughout its Phase 1a/2b Cystic Fibrosis study commenced in the month of ...
c (tobramycin inhalation powder) 28mg per capsule has obtained FDA approval for the treatment of bacterial lung infection in certain cystic fibrosis (CF) patients. TOBI Podhaler is new non-nebulized formulation and delivery system of ...
The sharemarket broke a 10-day winning streak yesterday after the US Federal Reserve said the country's economy had paused recently. However, the Australian bond market found support after a wave of selling. "Being the last day of the ...
Tags: stocks, US economy, sharemarket
The Australian sharemarket has closed slightly weaker, snapping a 10-day winning streak, after markets in the US fell. At 4.15pm AEDT, the benchmark S&P/ASX 200 index had fallen 17.9 points, or 0.37 per cent, at 4878.8 points, and the ...
Tags: Stocks, sharemarket, Ordinaries index
Genea Stem Cells Pty Ltd (GSC), a supplier and developer of disease-specific human stem cells, has announced that 25 of its disease specific embryonic pluripotent stem cell lines have been placed on the USA National Institutes of Health ...
Celerion has added a bronchoscopy suite in the Belfast, Northern Ireland, UK facility, to expand its respiratory capabilities. The company can perform bronchoalveolar lavage (BAL) using study participants from its database. The ...
The European Commission has granted marketing authorization for Pharmaxis' Bronchitol as an add on therapy to cystic fibrosis (CF). The company developed Bronchitol to aid clear the airways of CF patients. Pharmaxis CEO Alan Robertson ...
Tags: cystic fibrosis, CF, Pharmaxis'Bronchitol
The Anti-Infective Drugs Advisory Committee (AIDAC) to the US Food and Drug Administration (FDA) has recommended the use of Novartis's tobramycin inhalation powder (TIP) to treat cystic fibrosis (CF) patients whose lungs contain bacteria ...
Fresenius Kabi USA has announced the availability of Acetylcysteine Solution, USP, 20% 30ml vial for inhalation (mucolytic agent) or oral administration (acetaminophen antidote) to treat lung diseases. Acetylcysteine Solution, USP, ...
Tags: Acetylcysteine Solution, lung diseases, critical care products
Insmed has dosed first Cystic Fibrosis (CF) patient in the Clinical Evaluation of ARIKACE (CLEAR-108) phase 3 study of Arikace (liposomal amikacin for inhalation) in Europe. CLEAR-108 is a 300-patient randomized phase 3 trial comparing ...
Tags: Study of Arikace, pulmonary function, open-label safety study
US-based Cornerstone Therapeutics has entered into an agreement to acquire the US marketing rights to Chiesi Farmaceutici's BETHKIS (Tobramycin Inhalation Solution), designed for the treatment of cystic fibrosis patients with Pseudomonas ...
Tags: US-based Cornerstone Therapeutics, Chiesi Farmaceutici's BETHKIS
The US Food and Drug Administration(FDA)has granted orphan drug designation to Savara Pharmaceuticals'first inhaled antibiotic,designed for the treatment of pulmonary methicillin-resistant Staphylococcus aureus(MRSA)infection in cystic ...
Tags: Orphan Drug, Savara Pharma, FDA, inhaled antibiotic, MRSA
Pulmatrix has announced the results of a clinical study showing that an iCALM (inhaled cationic airway lining modulator therapy) attenuated allergen-induced bronchitis in susceptible asthmatic patients. The study concluded that iCALM is a ...